Compare · IART vs SNOA
IART vs SNOA
Side-by-side comparison of Integra LifeSciences Holdings Corporation (IART) and Sonoma Pharmaceuticals Inc. (SNOA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IART and SNOA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- IART is the larger of the two at $1.12B, about 203.1x SNOA ($5.5M).
- Both names hit the wire about 3 times in the past 4 weeks.
- IART has more recent analyst coverage (25 ratings vs 0 for SNOA).
- Company
- Integra LifeSciences Holdings Corporation
- Sonoma Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $1.12B
- $5.5M
- 1M return
- +6.47%
- -
- 1Y return
- +22.70%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 3
- 3
- Recent ratings
- 25
- 0
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Latest IART
- SEC Form SCHEDULE 13G filed by Integra LifeSciences Holdings Corporation
- Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
- Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
- SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation
- SEC Form 8-K filed by Integra LifeSciences Holdings Corporation
- Integra LifeSciences Reports Third Quarter 2026 Financial Results
- SEC Form 8-K filed by Integra LifeSciences Holdings Corporation
- Integra Announces Completion of Refinancing Transactions
- Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
- INTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 21.2% Share Drop
Latest SNOA
- SEC Form S-3 filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax
- SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.
- Amendment: SEC Form 8-A12B/A filed by Sonoma Pharmaceuticals Inc.
- SEC Form 8-K filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
- SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.